Printer Friendly

Innovus Pharma to commercialise Sensum+ in the EU following the CPNP notification.

M2 PHARMA-March 9, 2017-Innovus Pharma to commercialise Sensum+ in the EU following the CPNP notification

(C)2017 M2 COMMUNICATIONS

Pharmaceutical company Innovus Pharmaceuticals Inc (OTCQB Venture Market:INNV) reported on Wednesday the receipt of the CPNP notification number for the commercialisation of the Sensum+ in all 28 member countries of the EU.

According to the company, Sensum+ is a non-medicated cream which moisturises the head and shaft of the penis for enhanced feelings of sensation and greater sexual satisfaction. It is a patent-pending blend of essential oils and ingredients generally recognized as safe that recently commenced marketing in the US.

For the marketing of Sensum+ internationally, the company currently partners with Orimed in Canada, Tramorgen Limited in the UK, Elis Pharma in Turkey and certain select markets, BroadMed SAL for Lebanon, Ovation for Morocco, Khandelwal Laboratories PVT Inc for India, Nepal, Bhutan, Sri Lanka and Bangladesh, Tabuk Pharma for select Middle Eastern countries and Oz Biogenics for Myanmar and Vietnam.

Currently, Sensum+ is approved to be marketed and sold in 31 countries worldwide, including the US, Europe, India and Morocco. In addition to the US, it currently generates Sensum+ revenues from the the UK and Morocco, added the company.

The company stated the safety and efficacy of Sensum+ was evaluated in two post-marketing clinical survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+ twice daily for 14 consecutive days followed by once daily for eight weeks and as needed thereafter. Study participants reported a 50% increase in penile sensitivity with the use of Sensum+.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 9, 2017
Words:270
Previous Article:Bristol-Myers Squibb elects Thomas J. Lynch as EVP & CSO.
Next Article:BioCryst Pharmaceuticals announces public offering of USD45.0m common stock.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters